|
| Status |
Public on Nov 25, 2020 |
| Title |
MSC.MGUS2 |
| Sample type |
genomic |
| |
|
| Source name |
Bone marrow
|
| Organism |
Homo sapiens |
| Characteristics |
Sex: M
age: 61
donor: MGUS
batch: batch1
|
| Treatment protocol |
MSCs were recovered by trypsinization, washed once in PBS and stored at -20°C in DNA extraction buffer
|
| Growth protocol |
Primary MSCs from bone marrow (BM) samples of healthy donors (n=8), MGUS (n=10) and SMM (n=8), multiple myeloma (MM) patients (n=9) were generated as described by Garayoa et al. 2009 (PMID:19357701). Ficoll-Paque density gradient separation medium was used to isolate mononuclear cells from BM aspirates. MSCs were selected by adherence to plastic and subsequently expanded until passage 2 when they were used for experiments.
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
Genomic DNA was extracted using proteinase K according to standard protocols
|
| Label |
Cy3, Cy5
|
| Label protocol |
Standard Illumina Protocol
|
| |
|
| Hybridization protocol |
Bisulphite converted DNA was amplified, fragmented and hybridised to Illumina Infinium MethylationEPIC Beadchip using standard Illumina protocol
|
| Scan protocol |
Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting
|
| Description |
200325500026_R08C01
DNA methylation data from human clinical samples
|
| Data processing |
Rstudio
|
| |
|
| Submission date |
Sep 13, 2019 |
| Last update date |
Nov 25, 2020 |
| Contact name |
Esteban Ballestar |
| Organization name |
Josep Carreras Research Institute (IJC)
|
| Lab |
Epigenetics and Immune Disease
|
| Street address |
Ctra de Can Ruti, Camí de les Escoles s/n
|
| City |
Badalona, Barcelona |
| State/province |
N/A = Not Applicable |
| ZIP/Postal code |
08916 |
| Country |
Spain |
| |
|
| Platform ID |
GPL21145 |
| Series (2) |
| GSE137416 |
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease [methylation II] |
| GSE137419 |
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease |
|
